Core Insights - On October 30, Haisen Pharmaceutical experienced a slight decline of 0.26% with a trading volume of 24.34 million yuan [1] - The company reported a net financing outflow of 76.15 million yuan for the day, with a total financing and securities balance of 99.27 million yuan [1][2] - Haisen Pharmaceutical's main business revenue composition includes 85.62% from active pharmaceutical ingredients, 11.88% from intermediates, and 2.01% from formulations [1] Financing and Trading Activity - On October 30, Haisen Pharmaceutical had a financing buy-in of 1.49 million yuan, while the financing repayment was 2.25 million yuan [1] - The current financing balance of 99.27 million yuan accounts for 9.62% of the circulating market value, indicating a high level compared to the past year [1] - There were no short selling activities reported on the same day, with a short selling balance of 0 yuan, placing it in the high percentile for the past year [1] Financial Performance - As of September 30, Haisen Pharmaceutical had 11,500 shareholders, a decrease of 9.06% from the previous period [2] - The average number of circulating shares per shareholder increased by 9.96% to 3,363 shares [2] - For the period from January to September 2025, the company achieved a revenue of 359 million yuan, reflecting a year-on-year growth of 12.13%, while the net profit attributable to shareholders was 88.21 million yuan, up by 1.45% [2] - Since its A-share listing, Haisen Pharmaceutical has distributed a total of 51.45 million yuan in dividends [2]
海森药业10月30日获融资买入149.27万元，融资余额9927.22万元